{"id":7799,"date":"2026-02-24T06:08:28","date_gmt":"2026-02-24T06:08:28","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/melanotan-ii\/"},"modified":"2026-04-09T14:26:06","modified_gmt":"2026-04-09T21:26:06","slug":"mt-2","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/mt-2\/","title":{"rendered":"Melanotan II \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to Melanotan II product page<\/a><\/p>\n

\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on Melanotan II \u2014 for educational purposes only<\/p>\n

\nMC1R Activation and Melanogenesis Pathway<\/summary>\n
\n

Melanotan II activates melanocortin-1 receptors (MC1R) on melanocytes, triggering G\u03b1s-mediated cAMP accumulation. This activates protein kinase A (PKA), which phosphorylates CREB transcription factor, inducing MITF (microphthalmia-associated transcription factor) expression. MITF then upregulates melanogenic enzyme genes including tyrosinase, TRP-1, and TRP-2, resulting in increased eumelanin synthesis. MC1R variants (common in fair-skinned populations) show reduced cAMP response to \u03b1-MSH analogs.<\/p>\n

Dorr RT et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sci.<\/em> 1996. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nMelanocortin Receptor Structure-Activity Relationships<\/summary>\n
\n

MT-II was designed using structure-activity relationship (SAR) optimization of the \u03b1-MSH pharmacophore. Critical modifications include: (1) cyclization via lactam bridge between Asp and Lys, conferring protease resistance and receptor selectivity; (2) substitution of Met\u2074 with Nle (norleucine) preventing oxidation; (3) D-Phe\u2077 substitution enhancing binding affinity. These modifications result in approximately 100-fold greater potency than linear \u03b1-MSH at MC1R and extended plasma half-life from minutes to hours.<\/p>\n

Hruby VJ et al. “Structure-activity relationships and bioactivities of melanocortin analogs.” Ann N Y Acad Sci.<\/em> 1995. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nMT-II Phase 1 Human Pharmacokinetics<\/summary>\n
\n

A single-blind, placebo-controlled phase 1 pilot study studied MT-II in healthy male volunteers. Skin pigmentation was measured by reflectance spectroscopy over 7 days post-dose. Pharmacokinetic analysis showed plasma levels with Tmax<\/sub> of 1\u20132 hours. Skin melanin index showed significant increases compared to placebo. The study characterized the pigmentation response and documented the adverse event profile including nausea.<\/p>\n

Dorr RT et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sci.<\/em> 1996. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to Melanotan II product page Research Library Published research on Melanotan II \u2014 for educational purposes only MC1R Activation and Melanogenesis Pathway Melanotan II activates melanocortin-1 receptors (MC1R) on melanocytes, triggering G\u03b1s-mediated cAMP accumulation. This activates protein kinase A (PKA), which phosphorylates CREB transcription factor, inducing MITF (microphthalmia-associated transcription factor) expression. MITF then […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7799","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7799"}],"version-history":[{"count":1,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7799\/revisions"}],"predecessor-version":[{"id":8630,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7799\/revisions\/8630"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}